PD
ACRS icon

Point72 (DIFC)’s Aclaris Therapeutics ACRS Stock Holding History

Point72 (DIFC)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,132
Closed -$9.38K – 1504
2025
Q1 		$9.38K Buy
6,132
+2,424
+65% +$5.17K ﹤0.01% 1454
2024
Q4 		$9.2K Buy
3,708
+3,616
+3,930% +$9K ﹤0.01% 1345
2024
Q3 		$106 Sell
92
-18,227
-99% -$22.4K ﹤0.01% 1368
2024
Q2 		$20.2K Buy
+18,319
New +$21.5K ﹤0.01% 1232

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 (DIFC)'s ACRS Position: Q2 2025 in Review

Point72 (DIFC) sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 6,132 shares — an estimated $9.38K sold.

Point72 (DIFC) first reported a position in ACRS in Q2 2024 and held it in 4 quarters. The position peaked at $20.2K in Q2 2024. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Point72 (DIFC) reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 6,132 Aclaris Therapeutics shares in Q2 2025, an estimated $9.38K.
  • Point72 (DIFC) first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 4 quarters.
  • Point72 (DIFC)'s Aclaris Therapeutics position peaked at $20.2K in Q2 2024.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.